Leading the charge - pioneering treatments in the fight against neuropathic pain.
Kevin LEE, David Spanswick, Tracey Dickinson
pág. 555
Anthrax mounts a nuclear attack on glucocorticoid signaling.
Steven A. Kliewer
pág. 558
Katharine Pestell
pág. 559
pág. 560
Response to Ricciardolo: The functional significance of arginase in asthma is supported by gene expression.: The functional significance of arginase in asthma is supported by gene expression.
Herman Meurs, Johan Zaagsma, Harm Maarsingh
pág. 562
Uric acid: a novel treatment strategy for multiple sclerosis.: a novel treatment strategy for multiple sclerosis.
Ahmad Reza Dehpour, Kazem Mousavizadeh, Alireza Minagar
pág. 563
Response to Mousavizadeh et al.: Oxidative toxicity and glutamate excitotoxicity in multiple sclerosis.: Oxidative toxicity and glutamate excitotoxicity in multiple sclerosis.
Bernd C. Kieseier, Oliver Neuhaus, Juan J. Archelos
pág. 564
Neuroadaptive effects of active versus passive drug administration in addiction research.
Taco J. de Vries, Edwin H. Jacobs, August B. Smit
pág. 566
The annexin 1 receptor(s): is the plot unravelling?: is the plot unravelling?
Mauro Perretti
pág. 574
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
Nadia M.J. Rupniak, Markus Heilig, Andrew Holmes
pág. 580
Targeting thrombin - rational drug design from natural mechanisms.
James A. Huntington, Trevor P. Baglin
pág. 589
RAMPs: 5 years on, where to now?: 5 years on, where to now?
Maria Morfis, Arthur Christopoulos, Patrick M. Sexton
pág. 596
Divergence and complexities in DAG signaling: looking beyond PKC.: looking beyond PKC.
Marcelo G. Kazanietz, ChengFeng Yang
pág. 602
© 2001-2024 Fundación Dialnet · Todos los derechos reservados